Reuters logo
BRIEF-Soligenix says findings expected to facilitate potential approval of Rivax product
April 19, 2017 / 11:09 AM / in 6 months

BRIEF-Soligenix says findings expected to facilitate potential approval of Rivax product

April 19 (Reuters) - Soligenix Inc:

* Soligenix Inc - results from its ricin toxin vaccine (rivax™) development program will be presented at 20(th) annual conference on vaccine research

* Soligenix Inc - findings are expected to facilitate potential approval of Rivax product under U.S. FDA “animal rule”

* Soligenix Inc - Rivax has demonstrated “significantly enhanced” thermostability and 100% protection in preclinical ricin aerosol challenge models Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below